Early cancer diagnosis increases 4 times survival rate*
Early cancer diagnostic tests based on liquid biopsy concept, not only saves lives, but also bring significant reductions of the cost of cancer management in the health care systems.
*Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015. Data on file GA-2021-004.
What is
liquid biopsy?
A liquid biopsy is a blood-based diagnostic test that detects cancer DNA circulating in the bloodstream, referred to as “circulating tumor DNA” or more generally "cell-free DNA".
About EPI-CAN
Spin-off based on patent pending technology, developed at The Independent Clinical Epignetic Laboratory, Pomeranian Medical University in Szczecin, Poland.
Proof-of-concept
We have proofed that our solution can be used to detect and classify a cancer using liquid biopsy. Soon to be published in peer-review journal.